spacer
home > epc > autumn 2003 > editor's letter
PUBLICATIONS
European Pharmaceutical Contractor

Editor's Letter

I am writing this Editor's Letter in the middle of a British heatwave; and this time we really can call it a heatwave, with temperatures soaring over 30oC, and railway lines buckling! Temperatures are currently similar to those in San Antonio in June, where the 39th Annual DIA meeting was held. This meeting continues to grow in size, and this year it was bigger than ever, my only complaint being that there wasn't enough time to visit all the exhibition stands and attend all but a sample of the sessions.

I did, however, attend several of the sessions relating to outsourcing, but was disappointed that there seems to be little progress in improving the relationship between CRO and sponsor. The 'Preferred Provider Tug of War' was one title, which gives an idea of how the relationship is often viewed. The presentations supporting this title addressed how to make

it less of a struggle, and in a different session, classified as R&D Strategy, we heard about a strategic partnership between Solvay and Quintiles, which highlights how the sponsor/CRO relationship can develop to the benefit of both parties.

Included in this issue we have an article by Blair McCallum of McKinsey that describes the assessments of the benefits of outsourcing. While this article focuses on manufacturing, the 10 commandments given at the end could apply to any outsourcing relationship. The keys are clear communication, understanding the value proposition and clearly stated plans.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
1
     

There are no comments in regards to this article.

spacer
By Julia Lloyd-Parks
spacer
Julia Lloyd-Parks
spacer
spacer
spacer
John White
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Drive for generics sees Korea increasingly attractive to international pharma

Amsterdam, 31st July 2019: Already home to more than 40 pharmaceutical multinationals, Korea is on course to become a global biotech and pharmaceutical hub by 2025, driven by the surge of international partnerships, biosimilars, an expansion in the export of finished formulations and a robust generics market.
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement